In a xenograft model, we innovatively combined a CD38-inducing agent with CD38-targeting antibodies, revealing insights into CD38’s significance in CTCL pathology and suggesting novel treatment strategies. Here, CD38 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.